SVB Leerink Cuts Bluebird Bio (NASDAQ:BLUE) Price Target to $8.00
SVB Leerink Cuts Bluebird Bio (NASDAQ:BLUE) Price Target to $8.00
bluebird bio (NASDAQ:BLUE – Get Rating) had its target price trimmed by SVB Leerink from $9.00 to $8.00 in a report published on Monday morning, Benzinga reports. The brokerage currently has a market perform rating on the biotechnology company's stock. SVB Leerink also issued estimates for bluebird bio's Q4 2022 earnings at ($1.18) EPS, FY2022 earnings at ($5.13) EPS, Q1 2023 earnings at ($0.64) EPS, Q2 2023 earnings at ($0.62) EPS, Q3 2023 earnings at ($0.58) EPS, Q4 2023 earnings at ($0.48) EPS, FY2023 earnings at ($2.31) EPS and FY2024 earnings at ($1.59) EPS.
據Benzinga報道，在週一上午發佈的一份報告中，SVB Leerink將藍鳥生物(納斯達克：Blue-Get Rating)的目標價從9.00美元下調至8.00美元。該經紀公司目前對這家生物技術公司的股票進行了市場表現評級。SVB Leerink還發布了對藍鳥生物2022財年第四季度每股收益(1.18美元)、2022財年每股收益(5.13美元)、2023年第一季度每股收益(0.64美元)、2023年第二季度每股收益(0.62美元)、2023年第三季度每股收益(0.58美元)、2023年第四季度每股收益(0.48美元)、2023財年每股收益(2.31美元)和2024財年每股收益(1.59美元)的預期。
Other equities analysts have also issued reports about the stock. StockNews.com assumed coverage on shares of bluebird bio in a research report on Wednesday, October 12th. They issued a sell rating on the stock. Royal Bank of Canada dropped their price objective on shares of bluebird bio to $8.00 and set a sector perform rating on the stock in a research report on Tuesday, November 8th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. According to MarketBeat, bluebird bio currently has a consensus rating of Hold and an average target price of $6.75.
其他股票分析師也發佈了有關該股的報告。斯托克新聞網在10月12日星期三的一份研究報告中對藍鳥生物的股票進行了報道。他們對這隻股票發佈了賣出評級。11月8日，加拿大皇家銀行在一份週二的研究報告中將藍鳥生物的股價目標下調至8.00美元，並對該股設定了行業表現評級。三位分析師對該股的評級為賣出，六位分析師給出了持有評級，一位分析師給出了該公司的買入評級。根據MarketBeat的數據，藍鳥生物目前的共識評級為持有，平均目標價為6.75美元。
bluebird bio Trading Down 3.1 %
藍鳥生物交易下跌3.1%
NASDAQ BLUE opened at $6.33 on Monday. The firm has a market capitalization of $524.90 million, a P/E ratio of -1.04 and a beta of 0.99. The firm's fifty day moving average price is $7.38 and its two-hundred day moving average price is $6.52. bluebird bio has a 1 year low of $2.87 and a 1 year high of $8.58.
納斯達克藍週一開盤報6.33美元。該公司的市值為5.249億美元，市盈率為-1.04，貝塔係數為0.99。該公司的50日移動均線價格為7.38美元，200日移動均線價格為6.52美元。藍鳥生物的一年低點為2.87美元，一年高位為8.58美元。
Insider Activity at bluebird bio
藍鳥生物的內幕活動
In other bluebird bio news, Director Nick Leschly sold 4,290 shares of the stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $7.80, for a total transaction of $33,462.00. Following the sale, the director now directly owns 280,149 shares in the company, valued at $2,185,162.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 9,506 shares of company stock worth $72,088. Corporate insiders own 2.20% of the company's stock.
在其他藍鳥傳記方面，董事尼克·萊施利在1月11日星期三的交易中出售了4,290股藍鳥股票。這些股票以7.80美元的平均價格出售，總成交額為33,462.00美元。交易完成後，董事現在直接持有該公司280,149股股份，價值2185,162.20美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在這個環節。在過去的三個月裏，內部人士已經出售了9506股公司股票，價值72,088美元。企業內部人士持有該公司2.20%的股份。
Institutional Investors Weigh In On bluebird bio
機構投資者參與藍鳥生物
Large investors have recently bought and sold shares of the company. Caxton Associates LP grew its stake in bluebird bio by 559.6% during the second quarter. Caxton Associates LP now owns 220,154 shares of the biotechnology company's stock worth $911,000 after buying an additional 186,778 shares in the last quarter. Virtu Financial LLC bought a new position in shares of bluebird bio in the second quarter worth about $291,000. Monaco Asset Management SAM bought a new position in shares of bluebird bio in the second quarter worth about $1,267,000. WINTON GROUP Ltd bought a new position in shares of bluebird bio in the second quarter worth about $128,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of bluebird bio by 374.8% in the third quarter. Cubist Systematic Strategies LLC now owns 453,763 shares of the biotechnology company's stock worth $2,872,000 after acquiring an additional 358,196 shares during the last quarter. 79.01% of the stock is currently owned by institutional investors and hedge funds.
大型投資者最近買賣了該公司的股票。第二季度，Caxton Associates LP對藍鳥生物的持股增加了559.6%。Caxton Associates LP現在擁有220,154股這家生物技術公司的股票，價值911,000美元，上個季度又購買了186,778股。Virtu Financial LLC在第二季度購買了藍鳥生物的新頭寸，價值約29.1萬美元。摩納哥資產管理公司SAM在第二季度購買了藍鳥生物的新頭寸，價值約1,267,000美元。Winton Group Ltd在第二季度購買了藍鳥生物的新頭寸，價值約12.8萬美元。最後，立體主義系統戰略有限責任公司在第三季度增持了374.8%的藍鳥生物股票。Cubist Systems Strategy LLC在上個季度增持了358,196股後，現在擁有這家生物技術公司453,763股股票，價值2,872,000美元。79.01%的股票目前由機構投資者和對衝基金持有。
About bluebird bio
關於藍鳥傳記
(Get Rating)
(獲取評級)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
藍鳥生物公司是一家生物技術公司，研究、開發和商業化針對嚴重遺傳病的變革性基因療法。其用於治療嚴重遺傳性疾病的候選產品包括用於治療輸血依賴型β-地中海貧血的貝替貝吉基因Autotemcel；用於治療鐮狀細胞病(SCD)的lovotieglogene autemcel；以及用於治療大腦腎上腺腦白質營養不良的伊利伐多烯Autotemcel。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- 免費獲取StockNews.com關於藍鳥生物的研究報告(藍色)
- AMD仍是市面上最好的半導體股票之一
- 兩大股利大王：強生還是雅培？
- 網絡安全類股已經見底了嗎？
- 聯合太平洋，諾福克南方進入購買區
- 柔順治療公司的差距增加了34%：未來還會有更多的好處嗎？
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.
獲得藍鳥生物日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對藍鳥生物和相關公司的最新新聞和分析師評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。